Loading data for ALT — first visit, this takes a few seconds.
Altimmune Inc. (ALT)
NasdaqGM: ALT
· Real-Time Price · USD
3.24
+0.09 (2.86%)
At close: Aug 27, 2026, 2:53 PM
3.25
+0.31%
After-hours: 4:35 PM
The price, the headline numbers and the latest news, in one place.
Altimmune Inc. (ALT) Stock Price, Analysis & Data
2.86% (1D)
| Bid | 2.24 |
| Market Cap | 630.24M |
| Revenue (ttm) | 31K |
| Net Income (ttm) | -91.76M |
| 0.17 | |
| -0.76 | |
| n/a | |
| -4.85 | |
| P/B (ttm) | 1.33 |
| P/S (ttm) | 20330.24 |
| Earnings Date | Nov 5, 2026 |
| Ask | 3.92 |
| Volume | 2,229,777 |
| Avg. Volume (20D) | 4,407,630 |
| Open | 3.19 |
| Previous Close | 3.15 |
| Day's Range | 3.13 - 3.25 |
| 52-Week Range | 2.56 - 6.44 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | Jan 20, 2017 |
About ALT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg,...
Industry Biotechnology
Sector Healthcare
IPO Date May 26, 2017
Employees 57
Stock Exchange NasdaqGM
Ticker Symbol ALT
Website https://altimmune.com
Financial Performance
In 2025, Altimmune's revenue was 41K, an increase of 105% compared to the previous year's 20K. Earnings were -88.09M, a decrease of -7.33%.
Financial StatementsEarnings Surprise
Altimmune has released their quarterly earnings on Aug 12, 2026:
- Revenue of $0 misses estimates by $0, with -100.00% YoY decline.
- EPS of -0.12 misses estimates by 0.00, with 55.56% YoY growth.
Altimmune Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2